tiprankstipranks
Advertisement
Advertisement

NGNE Stock Latest News

Neurogene price target lowered to $65 from $70 at H.C. Wainwright
The FlyNeurogene price target lowered to $65 from $70 at H.C. Wainwright
8h ago
NGNE
Neurogene price target raised to $81 from $69 at Guggenheim
PremiumThe Fly
Neurogene price target raised to $81 from $69 at Guggenheim
8h ago
NGNE
TSHA
Neurogene price target lowered to $166 from $180 at Canaccord
PremiumThe Fly
Neurogene price target lowered to $166 from $180 at Canaccord
8h ago
NGNE
Neurogene Maintained at Buy as Rett Program Progress and Strong Cash Runway Offset Price Target Trim from $180 to $166
PremiumRatings
Neurogene Maintained at Buy as Rett Program Progress and Strong Cash Runway Offset Price Target Trim from $180 to $166
5d ago
NGNE
Neurogene Buy Rating Reaffirmed as NGN-401 Progresses; 12‑Month Price Target Trimmed from $70 to $65 on Model Updates and Financing Dilution
PremiumRatings
Neurogene Buy Rating Reaffirmed as NGN-401 Progresses; 12‑Month Price Target Trimmed from $70 to $65 on Model Updates and Financing Dilution
5d ago
NGNE
Analyst Maintains Buy on NGN-401 After Strong Rett Data and Cleared Safety Window, Trims Price Target to $63
PremiumRatingsAnalyst Maintains Buy on NGN-401 After Strong Rett Data and Cleared Safety Window, Trims Price Target to $63
6d ago
NGNE
Neurogene Advances Rett Gene Therapy Program and Extends Cash Runway to 2029
Premium
Company Announcements
Neurogene Advances Rett Gene Therapy Program and Extends Cash Runway to 2029
6d ago
NGNE
Neurogene reports Q2 EPS ($1.53), consensus ($1.38)
Premium
The Fly
Neurogene reports Q2 EPS ($1.53), consensus ($1.38)
6d ago
NGNE
NGNE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
NGNE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
12d ago
NGNE
Short Report: Ondas bearish bets at record highs
PremiumThe Fly
Short Report: Ondas bearish bets at record highs
1M ago
NGNE
NTST
Patrick Dolezal Raises Price Target to $65 and Reiterates Buy on NGN-401’s Differentiated Profile and Strong Embolden Study Design
PremiumRatings
Patrick Dolezal Raises Price Target to $65 and Reiterates Buy on NGN-401’s Differentiated Profile and Strong Embolden Study Design
1M ago
NGNE
Neurogene bolsters cash runway with equity offering
PremiumCompany Announcements
Neurogene bolsters cash runway with equity offering
2M ago
8K
NGNE
Neurogene prices 3.5M shares at $30.00 in public offering
PremiumThe FlyNeurogene prices 3.5M shares at $30.00 in public offering
2M ago
NGNE
Neurogene 75M Spot Secondary; re-offered at $30.00
Premium
The Fly
Neurogene 75M Spot Secondary; re-offered at $30.00
2M ago
NGNE
Neurogene announces common stock offering, no amount given
Premium
The Fly
Neurogene announces common stock offering, no amount given
2M ago
NGNE
Analyst Reiterates Buy on Neurogene as Rett Gene Therapy Data Strengthens Case; $180 Price Target Maintained
PremiumRatings
Analyst Reiterates Buy on Neurogene as Rett Gene Therapy Data Strengthens Case; $180 Price Target Maintained
2M ago
NGNE
Kapoor Reiterates Buy on NGNE, Citing Strong NGN-401 Data and Maintains $70 Price Target
PremiumRatings
Kapoor Reiterates Buy on NGNE, Citing Strong NGN-401 Data and Maintains $70 Price Target
2M ago
NGNE
Sami Corwin Reiterates Buy on Neurogene as NGN-401’s Strong Long-Term Rett Data De-Risk Embolden Trial and Support Favorable Risk‑Reward
PremiumRatings
Sami Corwin Reiterates Buy on Neurogene as NGN-401’s Strong Long-Term Rett Data De-Risk Embolden Trial and Support Favorable Risk‑Reward
2M ago
NGNE
Neurogene reports promising long-term NGN-401 Rett data
PremiumCompany Announcements
Neurogene reports promising long-term NGN-401 Rett data
2M ago
8K
NGNE
Neurogene announces data from Phase 1/2 trial of NGN-401
PremiumThe FlyNeurogene announces data from Phase 1/2 trial of NGN-401
2M ago
NGNE
Neurogene Earns Buy Rating as NGN-401 Shows Superior Efficacy in Rett Syndrome; $60 Price Target Reaffirmed
Premium
Ratings
Neurogene Earns Buy Rating as NGN-401 Shows Superior Efficacy in Rett Syndrome; $60 Price Target Reaffirmed
2M ago
NGNE
Neurogene: Buy Rating Reiterated as NGN-401 Rett Program Advances Toward BLA with $70 Price Target Unchanged
Premium
Ratings
Neurogene: Buy Rating Reiterated as NGN-401 Rett Program Advances Toward BLA with $70 Price Target Unchanged
2M ago
NGNE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >